SSP059 Monomil® XL 60mg modified-release tablet
The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) for Isosorbide Mononitrate (Monomil® XL) 60mg MR tablets in response to a significant ongoing supply disruption.
This SSP will enable community pharmacists in England, Wales, Scotland and Northern Ireland to supply patients with a different product as per the document below.
It allows a medicine from Group 1, in the first instance, or a medicine from Group 2, if Group 1 products are unavailable to be supplied against prescriptions for Monomil® XL 60mg MR tablets. The pharmacist must exercise their professional judgement to ensure the alternative product is suitable for the patient.
| Group 1 | Group 2 |
| Isosorbide mononitrate (Chemydur® 60XL) 60mg modified-release tablet | Isosorbide mononitrate (Monomax® XL) 60mg modified-release tablet |
| Isosorbide mononitrate (Relosorb® XL) 60mg modified-release tablet | Isosorbide mononitrate (Monosorb® XL 60) 60mg modified-release tablet |
| Isosorbide mononitrate (Isotard® 60XL) 60mg modified-release tablet | Isosorbide mononitrate (Tardisc®XL 60) 60mg modified-release tablet |
The choice of product is based on supply volumes and not clinical interchangeability. The total quantity supplied under this protocol should be equivalent to the number of days supplied on the original prescription.
SSP059 for Monomil® XL 60mg MR tablets will be in operation from Tuesday 26th March 2024 until Friday 3rd May 2024.
Please note that the SSP may be amended or revoked at any time, so contractors must ensure that the SSP is still valid before each supply.
Monomil® XL 60mg MR tablets SSP059